Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 14/20 | 0.81 |
| ▸ | IKBKB | O14920 | 4/20 | 0.71 |
| ▸ | CHUK | O15111 | 4/20 | 0.71 |
| ▸ | AKT1 | P31749 | 4/20 | 0.71 |
| ▸ | AKT2 | P31751 | 4/20 | 0.71 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.71 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6059500 | 1.00 | PADI4 (0.81) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6481544 | 0.97 | PADI4 (0.79) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6481546 | 0.97 | PADI4 (0.79) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6482805 | 0.96 | PADI4 (0.78) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6482806 | 0.96 | PADI4 (0.78) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6493835 | 0.95 | PADI4 (0.81) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6493833 | 0.95 | PADI4 (0.81) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL23511031 | 0.95 | PADI4 (0.76) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL6491632 | 0.93 | PADI4 (0.74) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL23511044 | 0.93 | PADI4 (0.78) | PADI4IKBKBCHUKAKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165053-A1 | Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-28 | — | — | US | claimed |
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | TES PHARMA S.R.L. (IT) | 2023-02-16 | — | — | US | disclosed |
| EP-4073054-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | Fondazione Istituto Italiano di Tecnologia (IT) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021116999-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-06-17 | — | — | WO | disclosed |
| EP-2968360-B1 | QUINOLINONE DERIVATIVES FOR THE INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10717739-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717739-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190345162-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2019-11-14 | — | — | US | disclosed |
| US-9695179-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695179-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20100168162-A1 | SELECTIVE INHIBITORS OF AKT AND METHODS OF USING SAME | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-07-01 | — | — | US | disclosed |
| EP-1404329-A4 | SUBSTITUTED 4-ARYL-3-(3-ARYL-1-OXO-2-PROPENYL)-2(1H)-QUINOLINONES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050165053-A1 | Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-28 | — | — | US | disclosed |
| EP-1404329-A1 | SUBSTITUTED 4-ARYL-3-(3-ARYL-1-OXO-2-PROPENYL)-2(1H)-QUINOLINONES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002098425-A1 | SUBSTITUTED 4-ARYL-3-(3-ARYL-1-OXO-2-PROPENYL)-2(1H)-QUINOLINONES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717739-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | BRPF3, BRD3, BRDT | PADI4 3814/4885IKBKB 1147/4885CHUK 1154/4885 |
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | RAD51, BRCA1, FANCI | PADI4 4745/4885IKBKB 1476/4885CHUK 1593/4885 |
| US-20190345162-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | BRPF3, BRD3, BRDT | PADI4 3814/4885IKBKB 1147/4885CHUK 1154/4885 |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | EIF4E, EIF4A1, EIF4A2 | PADI4 4191/4885IKBKB 1115/4885CHUK 724/4885 |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, BRD3, BRDT | PADI4 3814/4885IKBKB 1147/4885CHUK 1154/4885 |
| US-20050165053-A1 | Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, CASP2 | PADI4 1662/4885IKBKB 2485/4885CHUK 723/4885 |
| US-20100168162-A1 | SELECTIVE INHIBITORS OF AKT AND METHODS OF USING SAME | AKT1S1, AKT1, PIK3CA | PADI4 4192/4885IKBKB 183/4885CHUK 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.